This DLD25 session highlights the transformative potential of psychedelics in mental health treatment, the challenges of overcoming stigma, and the promising future of these therapies.
In conversation with Anne Philippi (The New Health Club), Genevieve and Steve Jurvetson share personal experiences and offer their perspective for psychedelic medicine to revolutionize mental health care.
Genevieve Jurvetson recounts how a family member’s struggle with heroin addiction led her to discover Ibogaine, a potent psychedelic used to treat opiate addiction.
Together with her husband, Steve, she launched a family foundation dedicated to mental health, funding pivotal research into substances like MDMA, psilocybin, and Ibogaine.
Steve Jurvetson, a well-known technology investor, see’s a wide range of applications for psychedelic medicines.
“It’s an absolute renaissance of possibilities, and they’re very pan-diagnostic”, he says, as the same therapy could work for many different conditions – “from eating disorders to anxiety disorders to, of course, depression, PTSD” and even “stroke and neurological diseases as well.”
The conversation also touches on the societal and economic potential of psychedelics to address the global mental health crisis, with current treatments often managing symptoms rather than tackling root causes.
